About the Study

Leukemia: An expanded access program of revumenib (SNDX-5613) in patients with relapsed or refractory leukemia with genetic alterations associated with HOXA overexpression

This expanded access program is for: • Patients who are older than 6 months old • Who have been diagnosed with acute leukemia with a gene alternation that has been associated with HOXA overexpression that has relapsed (has come back) or is refractory (has not responded to earlier treatment). • Who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options. This expanded access program will provide revumenib in a controlled clinical setting.

Interested in learning more?

Full Study Name: SNDX-5613-0707 EAP